Form 4 for BNGO Bionano Genomics, Inc.
Accepted 2022-05-16 00:00:00 ET · period of report 2022-05-13 · accession 0001209191-22-029459 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-05-16 | 2022-05-13 | BNGO | Stewart Christopher P. | CFO | M - OptEx | $0.56 | +60.0K | 121.6K | +97% | +$33.6K |
| D | 2022-05-16 | 2022-05-13 | BNGO | Stewart Christopher P. | CFO | M - OptEx | $0.00 | -60.0K | 117.5K | -34% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-13 | M | A | 60,000 | $0.56 | 121,579 | D | — | — | (F1) Includes 3,139 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan (the "ESPP") on June 10, 2021 and 2,940 shares acquired under the ESPP on December 10, 2021. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-05-13 | M | D | 60,000 | $0.00 | 117,500 | D | $0.56 · — to 2030-09-01 | 60,000 Common Stock | (F2) The shares vest in full on December 31, 2020, subject to Reporting Person's continuous service through December 31, 2020, subject to acceleration of vesting provided in the Employment Agreement, dated as of September 1, 2020, by and between the Issuer and the Reporting Person. |